

Grand Opening of Ferring Pharmaceuticals (China) Co Ltd - Zhongshan Manufacturing Site

China, Zhongshan, March 24, 2005 - Ferring Pharmaceuticals (China) Co Ltd has celebrated the grand opening of their Zhongshan manufacturing site located in Zhongshan port on 23 March 2005, the first production site of this Swiss company in Asia.

Ferring's Zhongshan manufacturing plant comprises 20,000 m². This GMP-compliant plant is designed to be a two-storey factory equipped with multiple production lines, including solutions for injection, lyophilized products, granules and enema, which will strengthen and facilitate Ferring's business development in Asia.

The late Dr. Frederik Paulsen, the founder of Ferring, was one of the first scientists to study and develop peptide hormone, believing that they could be used to supplement deficiencies and thus play an important role in the treatment of various life-threatening diseases. His theory has been proved remarkably accurate, and during the past five decades his company has grown from his original research.

Today, with in-house production sites in Europe, research centres in the United States and United Kingdom, the new Zhongshan plant in China, and a large-scale manufacturing plant being built in Saint-Prex, Switzerland; Ferring has become a pioneer in developing and selling pharmaceutical products based upon natural pituitary-produced peptide hormones, serving patients globally in over 70 countries. Ferring identifies, develops and markets innovative products in the diverse fields of urology, obstetrics and gynaecology, gastroenterology, and endocrinology.

Aiming to serve patients with the best and most appropriate products, Ferring is committed to a future in which it will continue to provide new and innovative medicines by utilizing existing skills, and developing pioneer technologies. The completion of Ferring's Zhongshan plant not only marks success in business development, but is also a valuable contribution to the pharmaceutical industry in China.

About Ferring:

Ferring is a Swiss-based research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, infertility and urology.

In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.

To learn more about Ferring or our products please visit us at www.ferring.com

Contact:

Michael George
Corporate Communication Manager
michael.george@fering.com
Tel.: +45 2878 72 09